Teva Pharmaceutical Industries Ltd. will offload 15 generic drug products and a host of pipeline opportunities to Impax Laboratories Inc. for $586m; the divestiture is part of an ongoing process to meet Federal Trade Commission antitrust requirements related to its pending acquisition of Allergan PLC's generics business, and follows other previously announced deals.
Impax said on June 21 that the new products will be immediately accretive to the generics specialist's 2016 bottom line...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
